Cat. No. 3405
Alternative Name: apoE(133-149)
Biological ActivityApolipoprotein (ApoE) peptide fragment that functions via the low-density lipoprotein receptor-related protein (LRP). Substantially reduces the symptoms of experimental autoimmune encephalomyelitis, a model of human multiple sclerosis, and suppresses inflammation, demyelination and infiltration of cells into the spinal cord. Also acts as a non-competitive antagonist at α7 nicotinic acetylcholine receptors (IC50 = 445 nM).
(Modifications: Leu-1 = N-terminal Ac, Leu-17 = C-terminal amide)
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Gay et al (2006) Apolipoprotein E-derived peptides block α7 neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes. J.Pharmacol.Exp.Ther. 316 835. PMID: 16249370.
Li et al (2006) Apolipoprotein E-derived peptides ameliorate clinical disability and inflammatory infiltrates into the spinal cord in a murine model of multiple sclerosis. J.Pharmacol.Exp.Ther. 318 956. PMID: 16740622.
Sheng et al (2008) N-methyl-D-aspartate receptor inhibition by an apolipoprotein E-derived peptide relies on low-density lipoprotein receptor-associated protein. Neuropharmacology 55 204. PMID: 18602124.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: COG 133, supplier, apoE, peptide, fragment, α7, alpha7, a7, nAChR, antagonists, NMDA, Nicotinic, Receptors, Acetylcholine, Glutamate, N-Methyl-D-Aspartate, iGluR, Ionotropic, COG133, apoE(133149), LDL, lipoprotein, apolipoproteins